1/ China “me-better” races ahead of $SANA 🇨🇳 SURPRISE! YTS109, an allogeneic CD19 STAR-T, just showed full lupus remissions in severe nephritis patients. While $SANA is still enrolling SC291, China already has human proof-of-concept. $SANA has Fast Track Designation from

With Keytruda going off patent in a couple of years, what are Merck doing on the innovation front to replace it? It turns out quite a bit behind the scenes. Our latest interview has the skinny... tinyurl.com/743cppsc

Excited to share our new paper in nature, led by Piotr Pawlik Kristiana Grigoriadis ! 🧬 We developed a new method, ALPACA, to untangle the co-evolution of single nucleotide variants and copy number changes in tumours. Check it out: tinyurl.com/yrppttr3

Summit Therapeutics' ivonescimab Western reality check: Why HARMONi may underperform relative to expectations – not everything new is gaudy... tinyurl.com/bdda73b3

$BNTX and DualityBio Announce Phase 3 Trial of ADC Candidate BNT323/DB-1303 Met Primary Endpoint of Progression Free Survival in HER2-Positive Metastatic or Unresectable Breast Cancer. investors.biontech.de/news-releases/…

While everyone has been chasing Summit lately, BMS may have grabbed the real prize with their bispecific ADC, Iza-Bren #WCLC25 tinyurl.com/2s3kc6kf

New nature study maps how our brains age at single-cell resolution. 🚨 Housekeeping genes (ribosome, metabolism, transport) are hit hardest, silenced by accumulated DNA damage + premature stop codons. Molecule Paul Kohlhaas bio/acc VitaDAO 💛 ARTAN Biotechnology

In our second critical review of data coming out of #WCLC25 today, we look at what might well be the modern sword of Damocles hanging over one company's head in lung cancer. Tomorrow could well result in a bloodbath... tinyurl.com/z5rs3uha

Ivonescimab’s $SMMT recent global misstep hands SSGJ-707 the high ground. It reshuffles the stakes in $PFE favor….if SSGJ-707 delivers both efficacy and survival signals in future trials, it could become the preeminent PD-1/VEGF bispecific, not just in China but worldwide.

Our critique of the $SMMT HARMONi data yesterday received some interesting comments in my inbox this morning. Just because a company says something is synergistic does not make it so in the clinic.

Wow, perhaps the biggest surprise of #WCLC25...

Uncovering gold at #WCLC25 in SCLC. Here we review a dozen agents across a number of different modalities and discovered the real winner wasn't an ADC at all... tinyurl.com/rh4dtp3c

Beyond the headlines, hype, and stylish PR, here's a look at 5 more studies from #WCLC25, some of which may be better or worse than they first appear! tinyurl.com/52k44f2a

Sometimes there's no smoke without fire. Beyond the rumour mill there is actually some new data worth looking at on the latest ADC target front – and good reasons why big Pharma might chase it: biotechstrategyblog.com/2025/09/why-bi…

Gosh this deadline comes around fast – seems like we were at the meeting only yesterday!

Not all patients respond to immunotherapy due to immune escape... what if we could change this with an unexpected approach to fixing antigen upregulation? tinyurl.com/5n7basjr

My all time favourite umpire!! RIP Dickie

My take on the Genmab-Merus acquisition - interesting times: biotechstrategyblog.com/2025/09/what-g…